Cited by 127Protein Tyrosine PhosphatasesAcute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia

Luo, J-M, Yoshida, H, Komura, S, Ohishi, N, Pan, L, Shigeno, K, Hanamura, I, Miura, K +6 more·2003·Leukemia

Abstract

The SH2 domain-containing inositol 5'-phosphatase (SHIP) is crucial in hematopoietic development. To evaluate the possible tumor suppressor role of the SHIP gene in myeloid leukemogenesis, we examined primary leukemia cells from 30 acute myeloid leukemia (AML) patients, together with eight myeloid leukemia cell lines. A somatic mutation at codon 684, replacing Val with Glu, was detected in one patient, lying within the signature motif 2, which is the phosphatase active site. The results of an in vitro inositol 5'-phosphatase assay revealed that the mutation reduced catalytic activity of SHIP. Leukemia cells with the mutation showed enhanced Akt phosphorylation following IL-3 stimulation. K562 cells transfected with the mutated SHIP-V684E cDNA showed a growth advantage even at lower serum concentrations and resistance to apoptosis induced by serum deprivation and exposure to etoposide. These results suggest a possible role of the mutated SHIP gene in the development of acute leukemia and chemotherapy resistance through the deregulation of the phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3)/Akt signaling pathway. This is the first report of a mutation in the SHIP gene in any given human cancer, and indicates the need for more attention to be paid to this gene with respect to cancer pathogenesis.

Integrity signals

Registry

Crossref · 10.1038/sj.leu.2402725

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., Naoe, T., Akao, Y., Ohno, R., & Ohnishi, K.
Affiliations
  • Hamamatsu University School of Medicine (JP)
  • Institute of Applied Biochemistry (JP)
  • Nagoya City University (JP)
  • Nagoya University (JP)
  • Aichi Cancer Center Hospital (JP)
Venue
Leukemia
Published
2003-01-01
Volume
17
Issue
1
Pages
1-8
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2026168267
Cited by
127
References
4
Citations by year
2026: 1 · 2025: 2 · 2023: 6 · 2021: 4 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 2 · 2012: 14
FWCI
2.99
Type
journal article
Language
en
Open access
closed
Locations
  • Leukemia (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords
ships, acute myeloid leukemia, dominant negative mutation, tumor suppressor, Akt phosphorylation, PI3K/Akt signaling, chemoresistance, apoptosis resistance, etoposide, interleukin-3, K562 cells, somatic mutations
MeSH terms
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Acute Disease, Animals, Antineoplastic Agents, Phytogenic, Chlorocebus aethiops, Etoposide, Genes, Dominant, Humans, Interleukin-3, Leukemia, Myeloid, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Transfection, Tumor Cells, Cultured, Case-Control Studies, Apoptosis, src Homology Domains, Drug Resistance, Neoplasm, COS Cells, Phosphatidylinositol 3-Kinases, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review